跳轉至內容
Merck
全部照片(1)

文件

890808P

Avanti

22:0 Trehalose

Avanti Research - A Croda Brand

同義詞:

D-(+)-trehalose 6,6′-dibehenate

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C56H106O13
CAS號碼:
分子量::
987.43
分類程式碼代碼:
12352211
NACRES:
NA.25

形狀

powder

包裝

pkg of 1 × 25 mg (890808P-25mg)
pkg of 1 × 5 mg (890808P-5mg)

製造商/商標名

Avanti Research - A Croda Brand

應用

vaccine development

運輸包裝

dry ice

儲存溫度

−20°C

SMILES 字串

O[C@H]([C@@H](COC(CCCCCCCCCCCCCCCCCCCCC)=O)O[C@H](O[C@@H](O[C@@H]([C@H]([C@@H]1O)O)COC(CCCCCCCCCCCCCCCCCCCCC)=O)[C@@H]1O)[C@@H]2O)[C@@H]2O

一般說明

22:0 Trehalose is a bioactive glycolipid and an analog of mycobacterial cord factor.

應用

22:0 Trehalose has been used as an adjuvant for Chlamydia vaccine. It has also been used as a component in adjuvant DMT (dimethyldioctadecylammonium/monophosphoryl lipid A/trehalose 6,6′-dibehenate (DDA/MPL/TDB)) to prepare DMT liposome adjuvanted CTT3H (polyprotein) vaccine.

生化/生理作用

Incorporation of trehalose 6,6′-dibehenate (TDB) into cationic liposomes composed of the quaternary ammonium compound dimethyldioctadecylammonium (DDA) produce an adjuvant system which induces a powerful cell-mediated immune response and a strong antibody response, desirable for a high number of disease targets. It acts as an immunomodulator. 22:0 Trehalose is considered less toxic and an efficient vaccine adjuvant for tuberculosis.

包裝

5 mL Amber Glass Screw Cap Vial (890808P-25mg)
5 mL Amber Glass Screw Cap Vial (890808P-5mg)

其他說明

For R&D use only. Not for drug, household, or other uses.

法律資訊

Avanti Research is a trademark of Avanti Polar Lipids, LLC

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Hong Yu et al.
Infection and immunity, 78(5), 2272-2282 (2010-03-17)
Major impediments to developing a Chlamydia vaccine lie in identifying immunologically relevant T-cell antigens and delivery in a manner to stimulate protective immunity. Using an immunoproteomic approach, we previously identified three immunodominant Chlamydia T-cell antigens (PmpG-1, PmpE/F-2, and RplF). Because
Xindong Teng et al.
Human vaccines & immunotherapeutics, 11(6), 1456-1464 (2015-04-24)
Different strategies have been proposed for the development of protein subunit vaccine candidates for tuberculosis (TB), which shows better safety than other types of candidates and the currently used Bacillus Calmette-Guérin (BCG) vaccine. In order to develop more effective protein

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務